PMID- 23806305
OWN - NLM
STAT- MEDLINE
DCOM- 20131017
LR  - 20130723
IS  - 1875-2128 (Electronic)
IS  - 1875-2128 (Linking)
VI  - 106
IP  - 6-7
DP  - 2013 Jun-Jul
TI  - Very late effects of dual chamber pacing therapy for obstructive hypertrophic 
      cardiomyopathy.
PG  - 373-81
LID - S1875-2136(13)00146-0 [pii]
LID - 10.1016/j.acvd.2013.04.003 [doi]
AB  - BACKGROUND: The very long-term effects of dual chamber pacing as a primary 
      treatment for hypertrophic obstructive cardiomyopathy (HOCM) are poorly known and 
      controversial. AIMS: To examine the intermediate- and long-term clinical and 
      haemodynamic effects of permanent dual chamber pacing in patients presenting with 
      HOCM. METHODS: Between 1991 and 2007, 51 patients (mean age 59 +/- 14 years) 
      presenting with HOCM and New York Heart Association (NYHA) functional class >/= II 
      despite optimal medical therapy underwent implantation of DDD pacemakers with or 
      without a defibrillator and were followed for 11.5 years (range 0.4-21.8 years). 
      RESULTS: During follow-up, no patient underwent myectomy or septal alcohol 
      ablation. NYHA functional class and other disease manifestations decreased 
      significantly over 1-2 years of follow-up and remained stable thereafter. The 
      left intraventricular (LV) gradient decreased by a mean of 78% over 1-2 years, 
      reaching 89% at end of follow-up, along with disappearance of systolic anterior 
      motion of the mitral valve. Mean LV ejection fraction decreased from a mean of 64 
      +/- 8% before pacing to 56 +/- 9% at end of follow-up (P=0.05), while LV 
      end-diastolic diameter did not change significantly. The 5- and 10-year actuarial 
      survival rates were 90% and 65%, respectively. Among 22 deaths, 10 were due to 
      cardiovascular and 12 to non-cardiovascular causes; two patients underwent 
      cardiac transplantation after 8 and 13 years of DDD pacing, respectively. 
      CONCLUSIONS: In this sample of patients with HOCM, DDD pacing alleviated symptoms 
      and improved haemodynamic function over the very long term. The merits of this 
      treatment should be revisited in a controlled trial.
CI  - Copyright (c) 2013. Published by Elsevier Masson SAS.
FAU - Lucon, Adrien
AU  - Lucon A
AD  - Cardiology Division, Rennes University Hospital, France.
FAU - Palud, Laurent
AU  - Palud L
FAU - Pavin, Dominique
AU  - Pavin D
FAU - Donal, Erwan
AU  - Donal E
FAU - Behar, Nathalie
AU  - Behar N
FAU - Leclercq, Christophe
AU  - Leclercq C
FAU - Mabo, Philippe
AU  - Mabo P
FAU - Daubert, Jean-Claude
AU  - Daubert JC
LA  - eng
PT  - Journal Article
DEP - 20130624
PL  - Netherlands
TA  - Arch Cardiovasc Dis
JT  - Archives of cardiovascular diseases
JID - 101465655
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cardiac Pacing, Artificial/adverse effects/*methods/mortality
MH  - Cardiomyopathy, Hypertrophic/diagnosis/mortality/physiopathology/*therapy
MH  - Chi-Square Distribution
MH  - Defibrillators, Implantable
MH  - Equipment Design
MH  - Female
MH  - Heart Transplantation
MH  - Hemodynamics
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Pacemaker, Artificial
MH  - Prosthesis Design
MH  - Recovery of Function
MH  - Retrospective Studies
MH  - Stroke Volume
MH  - Time Factors
MH  - Treatment Outcome
MH  - Ventricular Function, Left
MH  - Young Adult
OTO - NOTNLM
OT  - AV
OT  - Cardiomyopathie hypertrophique obstructive
OT  - Cardiomyopathy
OT  - Dual chamber pacing
OT  - HOCM
OT  - Heart failure
OT  - Hypertrophic obstructive cardiomyopathy
OT  - ICD
OT  - Insuffisance cardiaque
OT  - LV
OT  - LVOT
OT  - NYHA
OT  - New York Heart Association
OT  - RV
OT  - Stimulation cardiaque double-chambre
OT  - Traitement electrique
OT  - atrioventricular
OT  - hypertrophic obstructive cardiomyopathy
OT  - implantable cardioverter defibrillator
OT  - left ventricular
OT  - left ventricular outflow tract
OT  - right ventricular
EDAT- 2013/06/29 06:00
MHDA- 2013/10/18 06:00
CRDT- 2013/06/29 06:00
PHST- 2013/02/05 00:00 [received]
PHST- 2013/02/28 00:00 [revised]
PHST- 2013/04/16 00:00 [accepted]
PHST- 2013/06/29 06:00 [entrez]
PHST- 2013/06/29 06:00 [pubmed]
PHST- 2013/10/18 06:00 [medline]
AID - S1875-2136(13)00146-0 [pii]
AID - 10.1016/j.acvd.2013.04.003 [doi]
PST - ppublish
SO  - Arch Cardiovasc Dis. 2013 Jun-Jul;106(6-7):373-81. doi: 
      10.1016/j.acvd.2013.04.003. Epub 2013 Jun 24.